专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09376495B2 Deimmunized serum-binding domains and their use in extending serum half-life 有权
标题翻译：去免疫的血清结合结构域及其在延长血清半衰期中的应用
公开(公告)号：US09376495B2
公开(公告)日：2016-06-28
申请号：US14118516
申请日：2012-05-16
申请人： Ezio Bonvini , Bhaswati Barat , Ling Huang , Leslie S. Johnson
发明人： Ezio Bonvini , Bhaswati Barat , Ling Huang , Leslie S. Johnson
IPC分类号： A61K39/00 , C07K16/28 , C07K16/32 , C07K16/44
CPC分类号： C07K16/32 , C07K14/315 , C07K16/2803 , C07K16/2809 , C07K16/283 , C07K16/2851 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/567 , C07K2317/62 , C07K2317/624 , C07K2317/626 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2319/31 , C07K2319/32 , C07K2319/73
摘要： The present invention is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunized serum-binding protein. The invention also pertains to methods and uses that employ such molecules.
摘要翻译：本发明涉及包含能够结合所述血清蛋白的解除免疫的血清结合蛋白的多肽部分的多肽（例如，抗原结合分子）。如果缺乏去免疫的血清结合蛋白的多肽部分，则血清结合蛋白的存在相对于多肽的血清半衰期延长了多肽的血清半衰期。本发明还涉及使用这种分子的方法和用途。

2. 发明申请

US20150023964A1 FcgammaRIIB-Specific Antibodies and Methods of Use Thereof 审中-公开
标题翻译： FcgammaRIIB特异性抗体及其使用方法
公开(公告)号：US20150023964A1
公开(公告)日：2015-01-22
申请号：US14331360
申请日：2014-07-15
申请人： Leslie S. Johnson , Ling Huang , Robyn Gerena
发明人： Leslie S. Johnson , Ling Huang , Robyn Gerena
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
CPC分类号： C07K16/283 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2317/92
摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
摘要翻译：本发明涉及以比抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。本发明还提供抗FcγRIIB抗体或其抗原结合片段作为治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤，特别是B细胞恶性肿瘤的单一药物治疗的用途细胞性慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。本发明还提供了通过施用本发明的抗体来增强疫苗组合物的功效的方法。

3. 发明授权

US08216579B2 Humanized FcγRIIB-specific antibodies and methods of use thereof 有权
标题翻译：人源化FcγRIIB特异性抗体及其使用方法
公开(公告)号：US08216579B2
公开(公告)日：2012-07-10
申请号：US12785117
申请日：2010-05-21
申请人： Leslie S. Johnson , Ling Huang
发明人： Leslie S. Johnson , Ling Huang
IPC分类号： A61K39/395
CPC分类号： A61K39/39 , A61K2039/505 , A61K2039/55516 , C07K16/283 , C07K2317/24 , C07K2317/34 , C07K2317/52 , G01N33/564 , G01N33/6893 , G01N2800/24
摘要： The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.
摘要翻译：本发明涉及以比所述抗体结合FcγRIIA更大的亲和力结合人FcγRIIB的人源化FcγRIIB抗体，其片段和变体。本发明包括本发明的人源化抗体用于治疗与Fc受体介导的信号传导的平衡丧失有关的任何疾病（例如癌症，自身免疫性和炎症性疾病）的用途。本发明提供了通过施用本发明的人源化抗体来增强治疗性抗体的治疗效果以增强治疗性抗体的效应子功能的方法。本发明还提供了通过施用本发明的人源化抗体来增强疫苗组合物的功效的方法。本发明包括治疗自身免疫性疾病的方法和用于消除表达FcγRIIB的癌细胞的方法。

4. 发明授权

US08012476B2 Molecules with extended half-lives, compositions and uses thereof 有权
标题翻译：具有延长半衰期，组成和用途的分子
公开(公告)号：US08012476B2
公开(公告)日：2011-09-06
申请号：US12691433
申请日：2010-01-21
申请人： William Dall'Acqua , Leslie S. Johnson , Elizabeth Sally Ward
发明人： William Dall'Acqua , Leslie S. Johnson , Elizabeth Sally Ward
IPC分类号： C07K16/00 , A61K39/395 , C12P21/08 , C12N1/00
CPC分类号： C07K16/283 , A61K38/00 , A61K39/00 , A61K47/48507 , A61K47/6835 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K2/00 , C07K14/70503 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/94 , C07K2319/00 , C07K2319/30 , Y10S435/81
摘要： The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
摘要翻译：本发明提供了由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的IgG，非IgG免疫球蛋白，蛋白质和非蛋白质试剂的分子，其具有一个或更多的氨基酸修饰，其增加FcRn的恒定结构域或片段的亲和力。具有增加的半衰期的这种蛋白质和分子具有在这种分子的治疗，预防或诊断使用中需要更少量和/或更低频率给药的优点。

5. 发明申请

US20110152504A1 CD16A Binding Proteins and Use for the Treatment of Immune Disorders 审中-公开
标题翻译： CD16A结合蛋白和用于治疗免疫疾病的用途
公开(公告)号：US20110152504A1
公开(公告)日：2011-06-23
申请号：US12904554
申请日：2010-10-14
申请人： Leslie S. Johnson , Ling Huang , Hua Li , Nadine Tuaillon
发明人： Leslie S. Johnson , Ling Huang , Hua Li , Nadine Tuaillon
IPC分类号： C07K16/28
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/41 , C07K2317/732
摘要： CD 16A binding proteins useful for the reduction of a deleterious immune response asre described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimme hemolytic anemia.
摘要翻译： CD 16A结合蛋白可用于减少有害免疫反应。在一个方面，任选缺乏效应子功能的人源化抗-CD16A抗体用于治疗免疫疾病如特发性血小板减少性紫癜和自身免疫性溶血性贫血。

6. 发明申请

US20100196372A1 FcgammaRIIB Fusion Proteins and Compositions Thereof 审中-公开
标题翻译： FcgammaRIIB融合蛋白及其组合
公开(公告)号：US20100196372A1
公开(公告)日：2010-08-05
申请号：US12721887
申请日：2010-03-11
申请人： Leslie S. Johnson , Hua Li , Nadine Tuaillon
发明人： Leslie S. Johnson , Hua Li , Nadine Tuaillon
IPC分类号： A61K39/395 , A61P37/00
CPC分类号： C07K16/283 , A61K39/39541 , A61K2039/505 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2319/30 , C07K2319/32 , A61K2300/00
摘要： The present invention relates to molecules, preferably soluble (i.e., not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of an FcγR, derivatives and analogs thereof, and nucleic acids encoding same. Molecules of the invention are particularly useful for the treatment, management, or prevention of, or amelioration of one or more symptoms of, an autoimmune disease, especially for ameliorating serum platelet deficiency associated with immune thrombocytopenic purpura. The invention provides methods and compositions for enhancing the therapeutic efficacy of standard, current or experimental therapies for an autoimmune disease by administering a molecule of the invention.
摘要翻译：本发明涉及分子，优选可溶性（即非膜结合的）多肽，最优选包含FcγR的细胞外可溶性区域，其衍生物和类似物以及编码它们的核酸的可溶性融合多肽。本发明的分子特别可用于治疗，治疗或预防或改善自身免疫疾病的一种或多种症状，特别是用于改善与免疫性血小板减少性紫癜相关的血小板缺乏症。本发明提供了通过施用本发明的分子来增强用于自身免疫疾病的标准，当前或实验疗法的治疗功效的方法和组合物。

7. 发明授权

US07740851B2 Ultra high affinity neutralizing antibodies 失效
标题翻译：超高亲和力中和抗体
公开(公告)号：US07740851B2
公开(公告)日：2010-06-22
申请号：US10657363
申请日：2003-09-08
申请人： James F. Young , Leslie S. Johnson , William D. Huse , Herren Wu , Jeffry D. Watkins
发明人： James F. Young , Leslie S. Johnson , William D. Huse , Herren Wu , Jeffry D. Watkins
IPC分类号： A61K39/42 , A61K39/395
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/1027 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.
摘要翻译：公开了具有1010M-1甚至1011M-1范围内的结合亲和力的超高亲和力抗体。此类抗体包括具有新型高亲和力互补决定区（CDR）的抗体，特别是具有来自人或小鼠的骨架和恒定区的抗体。还公开了制备和筛选这些抗体的方法，以及使用它们来预防和/或治疗疾病，特别是病毒诱导的疾病的方法。

8. 发明授权

US07670600B2 Molecules with extended half-lives, compositions and uses thereof 有权
公开(公告)号：US07670600B2
公开(公告)日：2010-03-02
申请号：US11397328
申请日：2006-04-03
申请人： William Dall'Acqua , Leslie S. Johnson , Elizabeth Sally Ward
发明人： William Dall'Acqua , Leslie S. Johnson , Elizabeth Sally Ward
IPC分类号： C07K16/00 , A61K39/395 , C12P21/08 , C12N1/00
CPC分类号： C07K16/283 , A61K38/00 , A61K39/00 , A61K47/48507 , A61K47/6835 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K2/00 , C07K14/70503 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/94 , C07K2319/00 , C07K2319/30 , Y10S435/81
摘要： The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

9. 发明授权

US07635568B2 Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment 失效
公开(公告)号：US07635568B2
公开(公告)日：2009-12-22
申请号：US10900230
申请日：2004-07-26
申请人： James F. Young , Scott Koenig , Leslie S. Johnson , William D. Huse , Jeffrey D. Watkins , Herren Wu
发明人： James F. Young , Scott Koenig , Leslie S. Johnson , William D. Huse , Jeffrey D. Watkins , Herren Wu
IPC分类号： G01N33/53 , A61K39/12 , A61K39/42
CPC分类号： C07K16/1027 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565
摘要： The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.

10. 发明授权

US07553489B2 Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment 有权
标题翻译：给予/给予抗RSV抗体进行预防和治疗的方法
公开(公告)号：US07553489B2
公开(公告)日：2009-06-30
申请号：US11643982
申请日：2006-12-20
申请人： James F. Young , Scott Koenig , Leslie S. Johnson , William D. Huse , Jeffrey D. Watkins , Herren Wu
发明人： James F. Young , Scott Koenig , Leslie S. Johnson , William D. Huse , Jeffrey D. Watkins , Herren Wu
IPC分类号： A61K39/42 , A61K39/155
CPC分类号： C07K16/1027 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565
摘要： The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis of a RSV infection.
摘要翻译：本发明包括免疫特异性结合一种或多种RSV抗原的新型抗体及其片段，以及包含所述抗体和抗体片段的组合物。本发明包括预防人类呼吸道合胞病毒（RSV）感染的方法，包括向所述人施用预防有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段，其中一定的血清滴度为所述抗体或抗体片段在所述人受试者中实现。本发明还包括用于治疗或改善与人类RSV感染有关的症状的方法，包括向所述人施用治疗有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段，其中一定所述抗体或抗体片段的血清滴度在所述人受试者中实现。本发明还包括包含免疫特异性结合RSV抗原的抗体或其片段的组合物，以及使用所述组合物检测或诊断RSV感染的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式